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Phosphoribosyltransferases catalyze the displace-
ment of a PRPP a-10-pyrophosphate to a nitrogen-
containing nucleobase. How they control the balance
of substrates/products binding and activities is
poorly understood. Here, we investigated the human
adenine phosphoribosyltransferase (hAPRT) that
produces AMP in the purine salvage pathway. We
show that a single oxygen atom from the Tyr105
side chain is responsible for selecting the active
conformation of the 12 amino acid long catalytic
loop. Using in vitro, cellular, and in crystallo ap-
proaches, we demonstrated that Tyr105 is key for
the fine-tuning of the kinetic activity efficiencies of
the forward and reverse reactions. Together, our re-
sults reveal an evolutionary pressure on the strictly
conserved Tyr105 and on the dynamic motion of
the flexible loop in phosphoribosyltransferases that
is essential for purine biosynthesis in cells. These
data also provide the framework for designing novel
adenine derivatives that could modulate, through
hAPRT, diseases-involved cellular pathways.
INTRODUCTION
Purine metabolism plays an important role in nucleic acid syn-
thesis, energy-dependent reactions, and cellular signaling. This
process synthesizes adenosine (AMP), guanosine (GMP), ino-
sine (IMP), and xanthosine (XMP) nucleoside monophosphates
either de novo or through a salvage pathway (Nyhan, 2005a;666 Cell Chemical Biology 25, 666–676, June 21, 2018 ª 2018 ElseviZrenner et al., 2006). The recycling of purines is particularly
important during periods of rapid growth, such as embryogen-
esis or tumor proliferation (Pillwein et al., 1990; Weber et al.,
1987). Furthermore, the salvage pathway produces 90% of the
cellular nucleotide pool overall, with purines coming from either
nutrients or nucleotide catabolism via DNA andRNAdegradation
(Terkeltaub, 2012). Defects in purine homeostasis can lead to
severe disorders, such as cancer, gout, anemia, urolithiasis,
dystonia, intellectual disability, and immunodeficiency (Cebal-
los-Picot and Jinnah, 2016; Nyhan, 2005a, 2005b; de Vries and
Sperling, 1977).
The regulation of purine metabolism is controlled by a number
of key enzymes (Ceballos-Picot et al., 2015; Terkeltaub, 2012).
One such enzyme in the salvage pathway is the adenine phos-
phoribosyltransferase (APRT, EC 2.4.2.7). Deficiencies in this
enzyme lead to 2,8-dihydroxyadenine urolithiasis, and renal
and allograft failures (Bollee et al., 2010; Ceballos-Picot et al.,
2014; Zaidan et al., 2014). This enzyme with reversible activities
has an ordered sequential bibi reaction mechanism (Bashor
et al., 2002; Yuan et al., 1992). In the forward reaction, APRT syn-
thesizes AMP and inorganic pyrophosphate (PPi) from adenine
(ADE) and a-D-5-phosphoribosyl-1-pyrophosphate (PRPP) (Fig-
ure 1), using a divalent magnesium ion for catalysis. This is the
favored reaction with a Keq of around 10
5 for purified APRT
from Giardia lamblia, as estimated by Haldane’s representation
(Sarver andWang, 2002). In human cells, intracellular concentra-
tions of adenine and AMP have been determined to be 1 mM and
200 mM, respectively (Curto et al., 1997). The concentration of
PRPP and PPi, the other human APRT (hAPRT) substrates, are
estimated to be 10 mM and 90 mM, respectively (Heinonen,
2001). The corresponding apparent KMs of hAPRT with ADE,
PRPP, AMP, and PPi are of the order of 4 mM, 9 mM, 8 mM, and
100 mM, respectively (Murray, 1967; Silva et al., 2004). In the
forward reaction, ADE binds after PRPP, while in the reverseer Ltd.
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Figure 1. Chemical Structures of the hAPRT
Substrates (ADE, AMP, PRPP, and PPi) for
Both the Forward and Reverse Enzymatic
Reactions
Atom numbering is indicated in red. See also
Scheme S1.reaction, AMP binds prior to PPi (Scheme S1) (Bashor et al.,
2002). PRPP and AMP thus compete for the same site where
the latter also acts as a competitive inhibitor of the forward reac-
tion with a Ki value of 10.5 mM (Murray, 1967).
APRT refers to the type I phosphoribosyltransferase (PRT) fam-
ily, which belongs to the large glycosyltransferase family (EC 2.4.).
PRT structures are characterized by a Rossmann fold composed
of a common core region formed by five central parallel beta
strands flanked on each side by several alpha helices. The active
site of APRT consists of a 13-amino-acid-long PRPP-binding
motif, starting from Val123 in hAPRT, with a conserved
A131TGGS/T core sequence which serves to anchor the 50 mono-
phosphate group of either PRPP or ribonucleotides (Kabsch and
Sander, 1983; Phillips et al., 1999; Sievers et al., 2011) (Fig-
ure S1A). It also contains two adjacent aspartates (Asp127 and
Asp128 in hAPRT), two arginines (Arg67 and Arg87), and a spe-
cific cis-peptide bond, between Asp65 and Ser66, which hold
together the 20 and 30-OH of the ribose and the pyrophosphate
moiety of PRPP. The enzyme is a 180-amino-acid-long parallel
homodimer. The two active sites are in proximity and interact
via Arg87 from the opposite monomer. A hood region (amino
acids 14 to 28) confers substrate selectivity, and a flexible loop
(amino acids 99 to 110) usually closes over the binding site (Fig-
ure S1) (Eads et al., 1994; Schumacher et al., 1996; Shi et al.,
1999). In 2008, the structures of hAPRT in the substrate-free
form, as well as in the ADE-PRPP and AMP complexes were
elucidated (Silva et al., 2008, 2004). These structures exhibited
the expected fold of the type I PRT family. However, in the
ADE-PRPP-Mg2+ complex (PDB: 1ZN7), the flexible loop was
found in an unusual conformation with the conserved glutamate
104 oriented away from the adenine moiety (Silva et al., 2008).
This observation contrasts with previously published structures
of APRT enzyme from several other organisms (Phillips et al.,
1999; Shi et al., 2002) that show the equivalent glutamate in
hydrogenbonding distance to the ADEN7position. Such discrep-
ancies could relate to the fact that both the adenine and PRPP
moieties are poorly defined in the electron densitymap (Figure S2)
due to low occupancy of these substrates within the crystals
together with the hydrolysis of PRPP leading to a non-catalytically
active conformation of the enzyme (Deller and Rupp, 2015). MoreCell Chemicdetailed structural parameters for hAPRT
are therefore required to better under-
stand how the adenine and PRPP sub-
strates interact with and are processed
by the enzyme.
Here, we report structural and
biochemical studies with wild-type
hAPRT, along with comparative results
obtained with the hAPRT variant Tyr105-
Phe of the flexible loop. We present crys-
tal structures of wild-type hAPRT in com-plex with PRPP-Mg2+, ADE-PRPP-Mg2+, and AMP. We also
describe three structures of the Tyr105Phe hAPRT variant in
complex with ADE, PRPP andMg2+, which were obtained during
the enzymatic reaction time course. These structures allowed us
to demonstrate a loop motion-dependent catalytic activity dur-
ing a conversion, within crystals, of adenine and PRPP into
AMP and PPi. Moreover, we show that Tyr105 is essential for
driving hAPRT into a catalytically competent conformation,
allowing the product to form and preventing the inhibition by
AMP. This findings are relevant for other phosphoribosyltransfer-
ase enzymes and may pave the way for novel therapeutic appli-
cations against parasites (Berens et al., 1995; Gutierrez et al.,
2009) or purine-associated diseases (Bollee et al., 2012; Hertz
et al., 2013; Ceballos-Picot and Jinnah, 2016; Khan et al.,
2006). Our results are particularly important in the context of
Parkinson disease, for which the Parkinson-disease-related ki-
nase (PINK1) is implicated in dopaminergic neuron degeneration
and is regulated by adenine derivatives processed by hAPRT
(Hertz et al., 2013). Our data, therefore, offers potential new ap-
plications against neurodegenerative diseases in humans.
RESULTS
Structures of PRPP-Mg2+-, ADE-PRPP-Mg2+-,
and AMP-hAPRT
We first investigated the ligand-binding properties of hAPRT us-
ing differential scanning fluorimetry (DSF). Compared with the
substrate-free form, we found that the unfolding temperature
of the PRPP-bound enzyme was increased by 30C, which sug-
gests that PRPP protects the enzyme from thermodenaturation
(Table S1). Stabilizing effects of such magnitude are rarely
seen in proteins (Niesen et al., 2007). We also evidenced that
adding adenine (ADE) to the PRPP-bound enzyme did not stabi-
lize the complex further, since similar unfolding temperatures
(Tm) were observed. Finally, adding AMP to the substrate-free
protein stabilized the enzyme by only 10C. To further study
the role exerted by PRPP on hAPRT stability, we compared the
crystal structure of PRPP-Mg2+-bound hAPRT to the ADE-
PRPP-Mg2+ and AMP complex structures. hAPRT with freshly
prepared PRPP were co-crystallized using slightly modifiedal Biology 25, 666–676, June 21, 2018 667
Figure 2. Structure of PRPP-Mg2+-Bound hAPRTwt
(A) Overall structure of the human APRT homodimer showing two PRPP molecules (gray ball-stick), the hood region, and the flexible loop.
(B) Fo  Fc omit electron density map for PRPP contoured at 3s. Arg87 comes from the other subunit (molecule B).
(C) Octahedral coordination of the magnesium ion. Coordinating distances in A˚ are indicated in blue.
(D) Detail of the flexible loop in the open conformation of the PRPP-bound hAPRTwt structure showing the Tyr105 away from the active site. The Fo  Fc omit
electron densitymap for residue 102 to 107 is contoured at 3s. All the figures were generated with PyMOL (http://www.pymol.org/). The hydrogen bond distances
are indicated in A˚ and represented with dashed cyan lines and Mg2+ coordinating interactions are marked as black dashed lines throughout.
See also Figures S1, S4, and Tables S1 and S2.crystallization conditions from Silva et al. (2008). The first struc-
ture that only contains PRPP bound to a eukaryotic type I PRT
enzyme was obtained with crystals diffracting to 1.45 A˚ resolu-
tion in the P1 space group with a single homodimer per asym-
metric unit (Figure 2A, Table S2). One PRPP substrate was
bound to each molecule of the asymmetric unit. The Fo  Fc
omit density showed full occupancy of the site, where PRPP in-
teracts with all the components of its binding motif (Ala131,
Thr132, Gly133, Thr135, Asp127, and Asp128) demonstrating a
non-hydrolyzed substrate (Figure 2B). The pyrophosphate moi-
ety was stabilized by Ser66, Arg67, and Arg87 from the second
subunit of hAPRT and the magnesium ion. The latter exhibited
a canonic octahedral configuration, coordinating two water mol-
ecules and four oxygen atoms of the PRPP substrate with bond
distances varying between 2.2 and 2.4 A˚ (Figure 2C). We
observed a well-defined flexible loop that exhibited an open
conformation, with the conserved Glu104 and Tyr105 oriented
away from the active site, which terminated with a PRPP-
Tyr105 hydroxyl distance of over 14 A˚ (Figure 2D).668 Cell Chemical Biology 25, 666–676, June 21, 2018To investigate the role of the hAPRT flexible loop, we co-crys-
tallized the enzyme with ADE, Mg2+, and freshly prepared PRPP.
Fourteen days after crystallization, the crystals were harvested
and the structure determined. We found that both the PRPP
and ADE substrates were well ordered in all four subunits of
the asymmetric unit (Figures 3A, S3, and Table S2). The structure
of the PRPP substrate was superimposable with our PRPP-
bound hAPRT molecule (Figure 3A), which indicates that ADE
binding does not promote modifications in the PRPP-binding
site. ADE was found to interact with Val25, Arg27, Arg67, and
Glu104 through hydrogen bonds. On each side of the purine
plane, ADE maintained close van der Waals contacts with
Phe26, Tyr105, Leu129, and Leu159. In addition, the conserved
Tyr105 interacts through two hydrogen bonds with Arg67 and
the 10-pyrophosphate moiety. Tyr105 also positions its side
chain above ADE to prevent the solvent from accessing both
the N9 and C10 atoms where the chemical reaction takes place.
These contacts brought together both the flexible loop and the
hood region to cover the active site. The organization of these
Figure 3. Structures of the ADE-PRPP-Mg2+- and AMP-Bound hAPRTwt
(A) Fo  Fc omit electron density map for PRPP contoured at 3s.
(B) Superimposition of our PRPP-Mg2+- (yellow) and ADE-PRPP-Mg2+- (blue) hAPRTwt complexes onto the previously determined ADE-PRPP-Mg2+-hAPRTwt
structure (gray) (PDB: 1ZN7).
(C) Close-up view of the ligands after superimposition of the ADE-PRPP-Mg2+- onto AMP-hAPRTwt structures. ADE and PRPP are in blue, AMP inmagenta, along
with the corresponding amino acids in the active site.
(D) Structure of the AMP-hAPRTwt complex showing the flexible loop in an open conformation as in the PRPP-Mg2+-hAPRTwt structure.
See also Figures S1–S5 and Tables S1 and S2.two adaptable regions was different in our PRPP-bound struc-
ture compared with the previously reported ADE-PRPP-hAPRT
structure (Silva et al., 2008). This was illustrated by the displace-
ments of 2.9 A˚ of the alpha carbon of Val22 from the hood and of
6.3 A˚ of the alpha carbon of Tyr105 from the flexible loop in the
ADE-PRPP-Mg2+-hAPRT structure versus the PRPP-Mg2+-
bound structure (Figures 3B and S3E).
We could monitor product formation in solution using buffer
conditions identical to those used for crystallization, but the
kcat measured in our assay decreased by 15-fold compared
with a regular buffer (Tris, MgCl2) (Table 1; Figures S4A and
S4B). However, as clearly indicated by the structure, the forward
enzymatic reaction did not occur in the crystals, even after
14 days, as the two substrates (ADE and PRPP) and the magne-sium ion remain stable in the active site with full occupancy.
Therefore, we never visualized in crystallo enzymatic activity in
ADE-PRPP-Mg2+-hAPRTwt crystals despite a close distance of
3.2 A˚ between N9 from ADE and C10 from PRPP, which is a suit-
able distance to initiate the reaction.
Because AMP competes with PRPP for hAPRT activity, we
next compared our PRPP structure to an AMP-bound structure.
We diffused AMP molecules into substrate-free crystals and
resolved the structure to 1.5 A˚ resolution. The electron density
map in the active site was readily attributable to AMP (Fig-
ure S5A). The AMP structure was identical to the one published
by Silva et al. (2008) with a root-mean-square deviation (RMSD)
of 0.34 A˚. When we superimposed the AMP-bound structure
onto our ADE-PRPP-Mg2+-hAPRT structure (RMSD of 0.66 A˚),Cell Chemical Biology 25, 666–676, June 21, 2018 669
Table 1. Kinetic Parameters of the Forward and Reverse Reactions for hAPRTwt and hAPRTY105F
Protein Substrate Apparent KM
a (mM) kcat (s
1) kcat/KM (M
1.s1)
hAPRTwtb PRPP 16.8 ± 1.8 3.85 ± 0.35 2.3 105
ADE 6.1 ± 1.3 6.3 105
AMP ND > (8 ± 0.5) 104c ND
hAPRTY105Fb PRPP 0.85 ± 0.20 0.013 ± 0.003 1.5 104
ADE 2.9 ± 0.5 4.5 103
AMP ND > (8 ± 0.5) 104c ND
hAPRTwtd ADE 6.3 ± 2.0 0.26 ± 0.03 4.1 104
hAPRTY105Fd ADE 4.7 ± 1.2 0.012 ± 0.001 2.6 103
Protein Inhibitor Apparent Ki (mM) kcat (s
1) kcat/KM (M
1.s1)
hAPRTwtb AMP (vs PRPP) 23 ± 6
hAPRTY105Fb AMP (vs PRPP) 2.1 ± 0.6
Protein Inhibitor Apparent Keq (mM) kcat (s
1) kcat/KM (M
1.s1)
hAPRTwtb 16 ± 4
hAPRTY105Fb 18 ± 10
The values were calculated from the data of three independent experiments measured at 23C, unless otherwise stated. ND, not determined. See also
Figure S4.
aKM, apparent Michaelis-Menten constant for adenine and PRPP using our in vitro spectroscopic assay.
bData obtained in 100 mM Tris (pH 7.5) and 10 mM MgCl2.
cThese numbers are minimal values for the reactions due to a limited catalytic activity of the coupled reaction with human quinolinate phosphoribo-
syltransferase. These data were obtained at 37C.
dData obtained in crystallization solution: 85 mM Tris (pH 8.5), 5 mM MgCl2, 170 mM NaOAc, 17% PEG4000 and 15% glycerol.we found that both purine moieties were positioned in a similar
way with only a small rotation on the base of about 12. However,
we observed a large change in the ribose orientation in which the
C10 atom moved by 1.8 A˚ from the PRPP to the AMP configura-
tion (Figure 3C). The ribose moiety went from a 20-endo configu-
ration in the ADE-PRPP-Mg2+ complex to a 30-exo configuration
in the AMP-hAPRT structure. This also resulted in a 20OH move-
ment of 1.6 A˚. Similar to other AMP structures (Phillips et al.,
1999; Silva et al., 2008), the flexible loop in our AMP-hAPRT
complex was in the open conformation with Glu104 and
Tyr105 away from the active site (Figures 3D and S5B).
Tyr105 Prevents Strong Inhibition of hAPRT by AMP
and Favors the Forward Reaction
Out of the 12 amino acids of the flexible loop, Glu104 and Tyr105,
are strictly conserved in all species from bacteria to mammals
(Figure S1B). The role of Glu104 has already been established
in the Saccharomyces cerevisiae APRT. Glu104 is essential for
catalysis since a 106-fold decrease in reactivity was observed
with a Glu104Leu variant (Shi et al., 2001). In the Giardia lamblia
APRT structure, as in our ADE-PRPP-Mg2+-APRT (Figures 3A
and S3), the glutamate hydrogen interacts with the adenine N7
nitrogen atom, and it is suspected of playing a key role in the
N7 hydrogen abstraction that follows the N9-C10 bond formation
in the forward reaction (Shi et al., 2002).
The role of the Tyr105 has, however, never been investigated.
In our ADE-PRPP-Mg2+-APRT structure, Tyr105 is in contact
with both ADE and PRPP substrates in the closed conformation
of the flexible loop (Figures 3A, 3B, and S3E). It might therefore
play a role in the enzyme catalytic processes.
To determine the role of this conserved residue, we produced
and purified a Tyr105Phe variant, measured its kinetic proper-
ties, and compared them to the wild-type enzyme (Table 1 and670 Cell Chemical Biology 25, 666–676, June 21, 2018Figure S4). First, we checked that the wild-type hAPRT had
similar kinetic parameters compared with those previously re-
ported for various enzymes (Bashor et al., 2002; Shi et al.,
2001). Secondly, we found that, in the Tyr105Phe variant, the
apparent KM for PRPP and ADE were decreased, respectively,
by 20- and 2-fold, while the kcat/KM were decreased by 15-
and 140-fold, respectively. In addition, the kinetic equilibrium
constant Keq remained similar and around 20 for both enzymes.
We then investigated the reverse reaction using a coupled reac-
tion assay with human quinolinate phosphoribosyltransferase
(hQPRT) that we purified (the plasmid was a gift from Dr. Huant-
ing Liu and Prof. James Naismith from the University of St
Andrews, Scotland). Due to a limited activity of hQPRT in our
setup (kcat = 0.007 ± 0.002 s
1), we were unable to determine
an apparent KM value for AMP in the reverse reaction of wild-
type and variant hAPRT. However, we found that both the
wild-type and the hAPRTY105F variant displayed similar and min-
imal values for kcat of 8 3 10
4 s1 (Table 1), which were lower
than those reported for Leishmania donovani (1.25 s1) orGiardia
lamblia (0.01 s1) (Bashor et al., 2002; Sarver and Wang, 2002).
Finally, we tested the inhibitory action of AMP on the forward re-
action. We found that the Ki for AMP decreased 11-fold in the
variant as compared with the wild-type enzyme (Table 1, Figures
S4C and S4D). Therefore, the Tyr105Phe mutation increases the
inhibitory effect of AMP while decreasing the catalytic efficiency
of the enzyme in the forward reaction.
The APRT Tyr105 Drives Purine Biosynthesis In Vivo
We further probed the role of the Tyr105 in hAPRT by measuring
cell growth ofSaccharomyces cerevisiae in linewith purinemeta-
bolism. Wild-type and mutant hAPRTs were expressed in APRT-
free Saccharomyces cerevisiae, which is defective for de novo
purine synthesis (strain DS1-2b, a gift from R. Woods). We found
Figure 4. A Single Oxygen Atom, in the
Tyr105 Side Chain, Influences Catalysis
and Cell Growth
(A) Drop test viability assays in Saccharomyces
cerevisiae ade2 apt1 aah1 cells that express the
indicated hAPRT variants, grown on various pu-
rine-containing media.
(B–D) (B) Protein expression was estimated from a
western blot. a-Act1 corresponds to Actin anti-
body. Intracellular concentrations of ADE (C) and
ATP (D) in the yeast strains. Cells were transformed
with plasmids coding for wild-type hAPRT, vari-
ants, or by the cognate empty vector (). Cells
were grown on either adenine or hypoxanthine.
ND means not detected. The reported values are
best-fit means with SD representative of three
measurements.
See also Figure S4.that Saccharomyces cerevisiae expressing the Tyr105Phe
variant of hAPRT displayed a reduced growth rate in absence
of exogenous adenine, similar to the Glu104Leu variant,
compared with the wild-type (Figure 4A). Despite a decrease in
the kinetic efficiency of the Tyr105Phe variant, the magnitude
of the low-growth phenotype observed in yeast was not antici-
pated. These results were not due to low protein level of the
variant since its expression level was similar to the wild-type
enzyme (Figure 4B). To further investigate this growth phenotype
in connection with the protein activity, we measured the intracel-
lular concentrations of ADE and ATP in the cognate strain (Fig-
ures 4C and 4D). In contrast to yeasts expressing the wild-type
enzyme, we found that yeasts that expressed the Tyr105Phe
variant did not process ADE. ADE concentration within the cell
went up to 1 mM, as was the case in the absence of any hAPRT
expression. Consequently, we observed an extremely low intra-
cellular concentration of ATP in yeast expressing both variants
(Glu104Leu or Tyr105Phe). This ATP depletion is sufficient to
prevent cell growth. Similarly, the concentrations of AMP were
found to be 95 ± 7, 199 ± 17, 84 ± 20, and 87 ± 17 mM, respec-
tively, for cells transformed with an empty vector or with plas-
mids allowing the expression of either hAPRTWT, hAPRTE104L,
or hAPRTY105F. As a whole, these data indicate that Tyr105 of
the hAPRT catalytic flexible loop is critical to drive the enzyme
in the forward reaction and to fuel the production of ATP neces-
sary for cell growth.
In Crystallo Activity Shows that the Hydroxyl Group of
Tyr105 Is Essential to Select theBioactiveConformation
of the Dynamic Flexible Loop and to Form the Products
To gain structural insights into our cellular and kinetic results
from the Tyr105Phe variant and to investigate which determi-
nants are important for the enzyme turnover in crystallo,
hAPRTY105F was co-crystallized with ADE and PRPP in the pres-Cell Chemicence of magnesium ions (Table S2). Four-
teen hours post crystallization, the
crystals were harvested and frozen in
liquid nitrogen. The structure (called
hAPRTY105F–14hours) showed that Phe105
did not cap the ADE moiety as it does inADE-PRPP-Mg2+-hAPRT wild-type structures. Instead, the flex-
ible loop was in an open conformation and superimposable on
the loop conformation found in the PRPP-Mg2+- and AMP-
hAPRT structures (Figure 5A). In addition, although PRPP was
fully defined with a position identical to that in the PRPP-Mg2+-
hAPRT structure, ADE was not visible in the electron density
map (Figures S6A and S6B).
Fortuitously, we observed that, unlike the wild-type enzyme
crystals, the crystals of the hAPRTY105F variant cracked within
2 weeks (Figures S6C and S6D). Despite their appearance, these
crystals still diffracted X-rays to 1.55 A˚ resolution (Table S2),
14 days after crystallization at 20C (this structure is called
hAPRTY105F–14days). The molecules in the asymmetric unit
showed clear differences. The first hAPRTY105F–14days subunit
was bound to AMP, PPi, andMg2+ (Figure 5B), with the two latter
molecules having 50% occupancy. In the second subunit, PRPP
and Mg2+ were still largely present along with a density corre-
sponding to AMP having about 30% occupancy (Figure 5C),
which indicated a lower accumulation of the product in this sub-
unit. To further validate our findings, we collected data on the
same type of crystals, 30 days post crystallization at 20C (this
structure is called hAPRTY105F–30days). In this case, in the first
subunit, the AMP and PPi molecules were superimposable to
the ones after 14 days with identical occupancy; however, no
magnesium could be identified (Figure S7). In the second sub-
unit, AMP, PPi, and Mg2+ were all present and their occupancy
levels reached 100%, 60%, and 60%, respectively (Figure 5D).
This structure is superimposable to the first hAPRTY105F–14days
subunit with an RMSD of 0.4 A˚.
These results demonstrate that an enzymatic reaction has
occurred in crystallo without any inducer. This in crystallo enzy-
matic activity operates even though no density for the adenine
substrate was initially observed in the hAPRTY105F–14hours struc-
ture. These structures further show that a single oxygen atom onal Biology 25, 666–676, June 21, 2018 671
Figure 5. The Evolutionary Conserved
Tyr105 Is Essential for Loop Dynamics,
Active Site Formation and In Crystallo
Catalysis
(A–C) (A) Fo  Fc omit electron density map for
residues 102 to 107 contoured at 3s of the ADE-
PRPP-Mg2+-hAPRTY105F–14h structure. Fo  Fc
omit electron density maps contoured at 3s of the
ADE-PRPP- Mg2+-hAPRTY105F–14days complex
with AMP, Mg2+, and PPi in one molecule (B) and
AMP, Mg2+, and PRPP in the second molecule (C)
of the same homodimer.
(D) Fo Fc omit electron densitymaps for AMP and
PPi contoured at 3s for the second molecule of
the ADE-PRPP-Mg2+-hAPRTY105F–30days complex.
The electron density maps for the magnesium ion
(B and D) are contoured at 6s. Water molecules
coordinating the magnesium ions are not shown
for clarity.
See also Figures S6, S7, and Table S2.the Tyr105 side chain is responsible for selecting the conforma-
tion of the 12-amino-acid-long dynamic loop and thereby gener-
ating the active site of hAPRT. Accordingly, we showed that the
reaction occurs in a solvent with the same composition as the
crystallization solution. However, the kcat/KM value decreased
by 16-fold as compared with that of the wild-type hAPRTwt
(Table 1, Figures S4A and S4B).
DISCUSSION
Key Features of hAPRT for Substrates Binding in the
Forward and Reverse Reactions
First, our DSF analysis indicates that the binding of PRPP mark-
edly stabilizes the enzyme in solution as compared with the un-
bound form. This could be due to the numerous hydrogen bonds
formed by the PRPP-Mg2+ chelate with the enzyme (Figure 2B).
Interestingly, in all our crystal structures, the conserved Asp65-
Ser66 peptide bonds are in the cis conformation. In the sub-
strate-free yeast APRT structure, a cis bond has been observed
(Shi et al., 2001), while a trans peptide bond was found in sub-
strate-free APRT from Giardia lamblia (Shi et al., 2002) or
modeled in HGXPRT from Plasmodium falciparum (Roy et al.,
2015). We hypothesize that both conformations exist in solution
for the unliganded hAPRT. PRPP then selects the cis state of
hAPRT while binding to the active site. This phenomenon likely
contributes to the high protein stability observed after PRPP
binding.672 Cell Chemical Biology 25, 666–676, June 21, 2018Second, in spite of being a less efficient
variant enzyme in the forward reaction,
hAPRTY105F binds PRPP 20 times tighter
(Table 1). In parallel, the inhibitory effect
of AMP increases 11-fold, showing that
the variant also binds AMP with much
higher affinity than the wild-type enzyme.
These results suggest that one of the roles
of Tyr105 is to prevent the strong inhibition
of the forward reaction by AMP. In addi-
tion, since the kcat of the reverse reactionis similar in both the wild-type and variant enzymes, the
hAPRTY105F catalytic efficiency of the reverse reaction will be
greater than in the wild-type. Finally, in the forward reaction,
Tyr105 may also help the departure of AMP after catalysis.
Thirdly, our ADE-PRPP-Mg2+-hAPRTwt structure revealed crit-
ical roles for both the hood region and the catalytic flexible loop
(Figure 3B). PRPPwas unable to affect the conformation of these
features by itself. ADE, however, when bound to the active site
with PRPP, selects the loop and the hood to close into an active
conformation and to isolate ADE from the solvent. The only
atoms accessible to water molecules within a 4 A˚ distance
were the ones from the amino group at the C6 position of ADE,
which are away from the chemical reaction. By inspecting the
contacts made by the residues in the loop (Ala99 to Leu110),
we identified Glu104 and Tyr105 as being the major contributors
to this movement through the creation of new hydrogen bonds
and van der Waals contacts. To date, we and others have shown
that they are the only amino acid strictly conserved in the flexible
loop from prokaryotes to mammals (Figure S1B) (Phillips et al.,
1999; Shi et al., 2001). Together with their movement toward
the adenine and PRPP substrates, the aforementioned elements
are in favor of a critical role in the enzymatic reaction for these
residues, confirmed by a large decrease in the kcat value in our
Tyr105Phe variant (Table 1). The hood and loop movements,
which transform the active site into a productive conformation,
constitute the second strategy used by the enzyme to establish
selectivity after the cis-trans selection.
ADE + PRPP
Tyr105
AMP + PPi
Tyr105
Cellular growth
APRT
Flexible
loop
ADE + PRPP AMP + PPi
Phe105
Cellular arrest
APRT
Flexible
loop
Phe105
AMP
Figure 6. Model Showing a Global Evolu-
tionary Role of Tyr105 in APRTs
Tyr105 favors cellular growth as a consequence of
a flexible loop closing and limiting AMP inhibitory
effect in the forward reaction. See also Figure S4.Tyr105 Controls the Dynamics of the Catalytic
Flexible Loop
Our kinetic analysis showed that the catalytic efficiency in the
forward reaction is decreased by 15- and 140-fold for the
PRPP and ADE substrates, respectively (Table 1). This is slightly
higher than the observation of Shi et al. (2001), who showed that
the equivalent yeast APRT Tyr107Phe variant enzyme exhibited
a kcat/KM ratio that was decreased by 8- and 15-fold, respec-
tively, for PRPP and ADE, compared with the wild-type enzyme.
Several other studies suggested that Tyr105 could play a critical
role in the formation of AMP by isolating the active site from wa-
ter or by modifying the dynamics of the flexible loop (Jardim and
Ullman, 1997; Schumacher et al., 1996; Shi et al., 2001). With the
aim of exploring the role of Tyr105 in hAPRT activity at the struc-
tural level, we first noticed that, in the wild-type ADE-PRPP-
hAPRT crystals, the catalytic reaction did not occur, even
14 days post crystallization (Figures 3A, 3B, and S3). This was
surprising, firstly, because the distance between the N9 from
ADE and the C10 from PRPP was only 3.2 A˚, and, secondly, all
the components needed for the reaction to occur were present
within the crystal. In addition, we found that the enzyme can
catalyze the reaction in a solvent with the same composition
as in the crystallization mixture (Figure S4A and Table 1). By
investigating the macromolecular contacts, we observed that,
out of the four flexible loops present in the asymmetric unit, three
were not in contact with any symmetric molecules and were
potentially able to move in the solvent. If modeled in the open
state, the remaining loop would only contact Asp3 in the N termi-
nus of a symmetric molecule. The loop should therefore be able
to freely move away in a solvent channel. Therefore, crystal
packing is neither involved in preventing the wild-type flexible
loop from adopting an open conformation nor in preventing
catalysis. The ADE-PRPP-Mg2+-hAPRTwt enzyme is locked in
a yet-unexplained substrate-bound state within the crystal and
cannot evolve to form the expected AMP and PPi products.
The key elements to understand the way the reaction proceeds
further has not yet been described in the PRTases literature.
An answer comes from our analysis of the high-resolution
ADE-PRPP-Mg2+-hAPRTY105F structures obtained at differentCell Chemictimes after crystallization. At 14 hr post
crystallization, PRPP was clearly seen in
the electron density map at 1.55 A˚ resolu-
tion, whereas the second substrate, ADE,
was invisible despite a concentration in
the crystallization drop identical to the
one used for the crystallization of the
wild-type enzyme (Figures S6A and
S6B). In the hAPRTY105F–14hours structure,
the flexible loop was in an open confor-
mation, identical to that observed in our
PRPP- Mg2+- and AMP-hAPRT wild-type structures. By analyzing similar crystals 14 days or a month
later, we clearly identified both AMP and PPi, in the two subunits
of the asymmetric unit (Figures 5B–5D and S7). The forward re-
action proceeded fully in crystallo to generate the products for
this variant enzyme, and the substrates ADE and PRPP were
consumed. Surprisingly, the catalytic efficiency of the wild-
type enzyme is 16 times higher in the crystallization conditions
than the variant enzyme in the forward reaction (Table 1), yet
the reaction was not favored in the wild-type protein crystal.
Within the crystal of the variant, the loop may transiently
adopt a closed conformation, thereby allowing ADE to react
with PRPP. The loop would then move to the open conforma-
tion to allow AMP and PPi to form after the Glu104 proton
transfer. This process is possible as loop opening is favored
when Tyr105 is replaced by a phenylalanine. This reaction
populates the active site with the products in either a single
turnover process or upon the accumulation of products during
several catalytic cycles. We observed that the PRPP-Mg2+
and ADE-PRPP-Mg2+-bound complexes have identical
melting temperatures (Table S1). The enzyme with its loop in
an open conformation (PRPP-Mg2+-bound) is, therefore, as
thermostable as one with its loop in the closed conformation
(ADE-PRPP-Mg2+-bound). These results are consistent with
the 12,000 s1 rate of loop closure, determined by NMR,
during the dynamic motion of the flexible loop in wild-type
Salmonella typhimurium Orotate PRT (OPRT) bound to PRPP
(Wang et al., 1999). Hence, in a solution, the loop swings
easily from one conformation to the other.
We conclude that the enzymatic reaction requires dynamic
loop behavior and that it has to open to generate AMP and PPi
from adenine and PRPP. The presence of Tyr105 shifts the
loop to a closed conformation in the presence of an ADE-shaped
substrate, favoring the forward reaction. Then, the protonation of
Glu104 and the loop dynamics promote the formation and
release of products. The interaction of the Tyr105 hydroxyl group
with the 10-pyrophosphate moiety and Arg67 is the key to stabi-
lize the closed conformation and generate the products of
the forward reaction (Figure 6). This interaction is absent in
the Phe105 variant enzyme, which will preferentially select theal Biology 25, 666–676, June 21, 2018 673
open conformation. The latter will allow the enzymatic reaction to
proceed in crystallo.
It is well established that enzymatic reactions and protein
conformational changes can occur in the crystalline state.
Some of the first examples were reported in the 1960s while
studying globins (Chance et al., 1966; Perutz et al., 1964).
More recently, in crystallo enzymatic reactions have been re-
ported in a few other systems. In these instances, the reaction
was induced by X-rays (Berglund et al., 2002), through changes
in the oxidative environment (Yi et al., 2010), or by the addition of
a ligand (Hill et al., 2013; Jackson et al., 2008; Jensen et al.,
2010). Yet, our study reports an unusual in crystallo enzymatic
reaction that is firstly, not observed in the wild-type protein but
induced by a single mutation, and secondly, proceeds in the
crystal without the addition of other elements into the system.
In the Forward Reaction, Tyr105 Controls the Inhibitory
Role of AMP in Cells
The removal of the hydroxyl group from Tyr105, makes the
enzyme less efficient in the forward reaction, while it is the oppo-
site in the reverse reaction (Table 1 and Figure S4). These results
demonstrate that the open conformation of the loop favors the
reverse reaction by increasing its catalytic efficiency. It fully cor-
relates with our nucleotide complex structures in which the AMP
substrate interacts with hAPRT having the flexible loop in its
open conformation. It also correlates with our in vivo yeast
viability assay. Indeed, in the Tyr105Phe variant yeast, we found
that the intracellular concentration of adenine was 1 mM. The
substrate is therefore bioavailable for hAPRTY105F, which has a
KM of 2.9 mM. In addition, the intracellular concentration of
AMP is about 85 mM. Under similar conditions (Figure S4D),
hAPRTY105F has a Ki for AMP versus PRPP 40 times lower
(2.1 mM) than the concentration of AMP within cells (Table 1).
This makes AMP a saturating substrate for hAPRTY105F, and to
a lesser extent hAPRTwt. Since the binding site is specific to
AMP and not to other nucleoside monophosphates, such as
IMP or GMP (with Ki of around 200 mM; Murray, 1967), AMP
must act as an inhibitor of the forward reaction for the
hAPRTY105F variant in which the flexible loop preferentially stays
in the open conformation. Hence, in the presence of AMP, the
forward reaction cannot occur resulting in an accumulation of
ADE and a large depletion of ATP along with a concomitant
decrease in cell growth (Figures 4A, 4C, and 4D). These results
illustrate the evolutionary selection pressure to strictly conserve
Tyr105 in APRT in all organisms, from prokaryotes to eukaryotes
(Figure S1B). Other amino acids in the flexible loop may also
contribute to control its dynamic function and the kinetic
parameters of the forward and reverse reaction. Further struc-
tural and biochemical studies would be needed to identify
them. In summary, the forward reaction in APRT is under the
control of ADE, PRPP, and AMP concentrations, the latter acting
as a feedback mechanism under the control of both the tyrosine
105 and the flexible loop dynamics.
Conclusions
Our findings enabled us to identify a key residue in hAPRT that
effects the catalytic efficiencies of both the forward and reverse
reactions in order to sustain cell survival when adenine is the sole
purine source. This residue has been strictly conserved through674 Cell Chemical Biology 25, 666–676, June 21, 2018evolution to control catalysis and the dynamics of the flexible
loop. We also show an in crystallo catalytic activity induced by
a change in protein dynamics and specificity. Finally, since N6
in adenine is the only atom exposed to water molecule within a
4 A˚ radius in the ADE-PRPP-Mg2+-hAPRTwt structure, this
chemical group can be modified to give novel adenine analogs
with specific functions. These analog modifications could be
easily performed using our ADE-PRPP-Mg2+-hAPRTwt structure
as template. Such a compound like cytokinin nucleobases are
also substrates of plant APRTs and they play an important role
in plant development (Zhang et al., 2013). In addition, a similar
analog affects the Parkinson-disease-related kinase (PINK1)
pathway. This analog is the precursor of KMP through hAPRT
(Hertz et al., 2013). Together with recently solved PINK1 struc-
tures (Kumar et al., 2017; Schubert et al., 2017), our data provide
a scaffold to explore small molecule modulators of the PINK1
pathway.
SIGNIFICANCE
The recycling of purines, through the salvage pathway, is an
important process for cell homeostasis. It participates in
nucleic acid synthesis, energy-dependent reactions, and
cellular signaling. The structures of human adenine phos-
phorybosyltransferase (hAPRT) reveal its substrate’s speci-
ficity in both directions of the reaction along with a dynamic
motion of its catalytic loop. Our kinetic and structural ana-
lyses of a structure-based variant provide a rationale for
the central role of a conserved tyrosine in kinetic parame-
ters’ control of the forward and reverse enzyme activities.
These findings give newopportunities tomodulate the activ-
ities of other members of the PRT family. These data also
provide the framework to design other adenine derivatives
modified at the N6 position. These compounds will be pro-
cessed by hAPRT and used to regulate other pathways
within cells. This strategy has already been observed in the
Parkinson-disease-related kinase (PINK1) or plant cytoki-
nins pathways and could therefore be developedwith poten-
tial applications in crop development or cure for neuronal
diseases in humans.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Saccharomyces cerevisiae DS.1-2B/1 strain with genotypeMAT alpha ade2 apt1 aah1 ura3were used in this study. Cells were grown
in a SD synthetic minimal medium containing 5% ammonium sulfate, 0.17% yeast nitrogen base (Difco), 2% glucose supplemented
with 0.2% casamino acids (Difco) and tryptophan (0.2 mM) and either adenine (0.3 mM) or hypoxanthine (0.3 mM).
METHOD DETAILS
Protein Purification and Crystallization
The hAPRT wild type protein was purchased from Euromedex (France) (catalog number: ATGP0483, lot: 1046601). The protein prep-
aration was done at 4C. The protein was diluted four times into buffer A (20 mM Tris-HCl pH 7.4, 5 mMMgCl2) with a 50-fold dilution
factor and concentrated each time. A final concentration to 5 mg.ml-1 was performed as assessed by UV/visible spectroscopy using
an estimated absorption coefficient ε(280 nm) = 41,200 M-1cm-1. To prepare ADE-PRPP-Mg2+-hAPRTwt co-crystals, the protein was
first mixed with a 400 mM concentrated solution of PRPP in a 20:1 volume ratio (final PRPP concentration of 20 mM). Then, a satu-
rated solution of ADE was added in a 20:1 volume ratio. All the solutions were prepared in buffer A and the final protein concentration
of the complex was 4.5 mg.mL-1. The PRPP-Mg2+-hAPRT complex was prepared by buffer exchanging hAPRT with 500 mM PRPP-
containing buffer A as described above, and concentrating the complex to 11mg.ml-1. Using aMosquito robot (TTP LabTec), 400 nL
of each complex was mixed with 200 nL of crystallization solutions made of 85 mM Tris-HCl pH 8.5, 170 mM NaOAc and 19-21%
PEG4000 mixed with 0-30 % glycerol. The plates were incubated at 20C and crystals appeared overnight. The adenine containinge2 Cell Chemical Biology 25, 666–676.e1–e4, June 21, 2018
crystals were transferred to a cryo-solution made of the crystallization solutions supplemented with 25% glycerol before being flash
frozen in liquid nitrogen. PRPP-Mg2+-hAPRT crystals were directly frozen in liquid nitrogen a couple of days after growth. The storage
of the PRPP-Mg2+-hAPRT crystals for one month at 20C led to a complete hydrolysis of the PRPP, which left a free active site with a
single phosphate ion bound. To prepare the AMP-hAPRT complex, we transferred these substrate-free crystals into crystallization
solutions containing 20mMAMP for 45 minutes. We repeated this transfer three times to insure full occupancy for AMP in the hAPRT
active site. The crystals were then frozen immediately in liquid nitrogen. After cloning the gene in a pET24d plasmid, the hAPRTY105F
variant was induced with 0.5 mM IPTG and expressed in BL21(DE3) E. coli cells in Terrific Broth media (MoBio). After three days at
28Cwith shaking at 100 rpm, the cells were centrifuged and frozen in liquid nitrogen. A pellet corresponding to 1.6 L culture was then
mixed with 70 mL of buffer A and sonicated for 4 minutes. After centrifugation at 24,500 rpm for 45 minutes, the supernatant was
diluted two-fold in buffer A and applied onto a 5mL Q sepharose (GE, 17-0510-10) column equilibrated in the same buffer. Human
APRTY105F eluted during anNaCl gradient at a conductivity of approximately 8mS. The protein thenwas diluted 10 fold in buffer A and
applied onto a 5 mL AMP-agarose resin (Sigma, A1271). The resin was washed with 30 column volumes of buffer A and the protein
was eluted in 10 mL of buffer A containing 5 mM AMP. After concentrating the protein sample to 2 mL, it was applied onto a prepar-
ative gel filtration column (GE, 17-1069-01) equilibrated in buffer A which contained 150mMNaCl. The protein eluted as a single peak
with an elution volume corresponding to a dimer, as analyzed from a calibration curve. The sample was concentrated and rapidly
mixed with a PRPP solution saturated with ADE in a 10:12 ratio to obtain final concentrations of 5 mg/mL of protein and 16.7 mM
PRPP. The same crystallization solutions as above were then used to prepare the ADE-PRPP-hAPRTY105F crystals. The human
QPRT plasmid (pEHIShqprt) was a gift from Dr. Huanting Liu and Prof. James Naismith from the University of St Andrew, Scotland
(Liu et al., 2007). The human QPRT (hQPRT) was induced with 0.5 mM IPTG and expressed in BL21(DE3) E. coli cells in Terrific Broth
media. After one day at 20Cwith shaking at 190 rpm, the cells were centrifuged and frozen in liquid nitrogen. A pellet corresponding
to 2.4 L culture was then mixed with 90 mL of buffer B (50 mM NaH2PO4, pH = 7.0, 350 mM NaCl, 5% Glycerol) and sonicated for
4 minutes. After centrifugation at 24,500 rpm for 45 minutes, the supernatant was applied onto a 2 mL Ni-NTA affinity column (GE,
17-5318-02). After three washes with 50 mL of buffer B, the protein was eluted in 200 mM imidazole-containing buffer B. The sample
was then concentrated to 2 mL and applied onto a preparative gel filtration column (GE, 17-1069-01) equilibrated in buffer C (50 mM
KH2PO4, pH = 7.5, 5 mMMgCL2, 200mMNaCl). The sample was concentrated to 2-5 mM and use rapidly in a coupled kinetic assay
together with hAPRT.
Data Collection, Processing and Structure Refinement
Six diffraction data were obtained at SOLEIL (beamline PX2) and ESRF (beamlines ID14-4, ID23-2, ID29 and ID30a) (Table S2). They
were integrated with iMOSFLM (Leslie and Powell, 2007) or XDS (Kabsch, 2010) and scaled with_ENREF_51 AIMLESS (Evans and
Murshudov, 2013). The PRPP-Mg2+-hAPRT structure was obtained by molecular replacement with the program PHASER (McCoy
et al., 2007), using phases from the PDB_ID code 1ZN7 structure (Silva et al., 2008). The other structures were also solved by the
molecular replacement method using our PRPP-Mg2+-hAPRT structure as initial models. Complex structures were then refined
with REFMAC5 (Murshudov et al., 1997) using the CCP4i software suite (Winn et al., 2011)_ENREF_54 and the building program
COOT (Emsley et al., 2010).
Differential Scanning Fluorimetry Assays
The thermal stability of purified APRT protein was analyzed using a LightCycler 480 instrument (Roche) to image 384-wells
simultaneously. The protein was diluted to 0.2 mg/ml in 20 mM Tris-HCl pH 7.4, 150 mM NaCl. This buffer maximized the fluores-
cence response. All the chemicals (ADE, PRPP, PPi, AMP) were used at the same concentrations in all the experiments (1 mM final
concentration in 1%DMSO). Optical foil was used to cover the PCRmicroplates (Roche). The plates (containing a total of 10 mL/well)
were centrifuged, placed in the LightCycler apparatus and the temperature of protein solution gradually increased from 30 to 95C at
0.01C per second with 16 acquisitions per degree. The protein stability was assessed by measuring the fluorescence of a reporter
dye, SYPRO orange (Invitrogen, Carlsbad, S6651), diluted 1000-fold as recommended by the manufacturer, which interacts specif-
ically with the hydrophobic patches of the protein. Filters were adjusted to the optimal excitation and emission wavelengths for
SYPROOrange (Ex 465 / Em 580 nm). Each experiment was performed in triplicate in order to compute themean value of the thermal
melting profile (Tm) and its standard deviation.
In Vitro hAPRT Kinetic Analysis
In the forward reaction, human wild-type APRT and Tyr105Phe variant activities were determined by quantifying the amount of AMP
produced using a spectroscopic assay identical to the one developped in J.V. Tuttle et al. (Tuttle and Krenitsky, 1980). Analyses were
performed in 0.1 M Tris-HCl pH 7.5, 10 mMMgCl2 (buffer D), or in the crystallization buffer 85 mM Tris pH=8.5, 5 mMMgCl2, 170 mM
NaOAc, 17% PEG4000 and 15% glycerol. The latter solution needed to be prepared freshly so as not to give a signal at 256 nm. The
reaction mixture (200 mL final volume) was incubated at 23C. When ADE was varied, 500 mM of PRPP were added to the mixture.
When PRPP was varied, 50 mMof ADE were added to the mixture. The wild type protein concentration used was 200 nM and 600 nM
respectively in buffer D and crystallization buffer. For the variant enzyme, the protein concentration used was 2 mMand 4 mM respec-
tively in buffer D and crystallization buffer. The reaction started after the addition of the enzyme and was monitored at 256 nm, where
the differential of the absorbance ismaximumbetween AMP and ADE and equal to 2,100M-1.cm-1 (Tuttle and Krenitsky, 1980). Inhib-
itory constant (Ki) of AMP versus PRPP were calculated using 0, 20 and 80 mM concentration of AMP in the reaction mixture. TheCell Chemical Biology 25, 666–676.e1–e4, June 21, 2018 e3
equilibration constant (Keq) were calculated at equilibrium as [AMP][PPi]/[ADE][PRPP] while incubating equimolar concentration of
ADE and PRPP and measuring the molar concentration of AMP formed (also equal to the concentration of PPi). The kinetic param-
eters were determined with the Michaelis-Menten equation using Origin 6.1 with a hyperbolic fit. For the reverse reaction, a coupled
enzymatic reaction similar to the one described in Bashor et al. was used (Bashor et al., 2002). The reaction mixture (60 mL final
volume) was incubated at 37C. AMP, PPi and quinolinic acid (QA) were respectively added at 1.0, 0.5 and 0.5 mM final concentra-
tion. HumanQPRT (ε = 26,900M-1.cm-1) and hAPRTwere then added at 25 and 10 mM, respectively. After a 30-minute incubation, the
reaction was stopped by addition of 60 mL of 2M KCN. The nicotinic acid mononucleotide (NaMN) derivative was then monitored at
315 nM with an absorbance coefficient of 5,500 M-1.cm-1 (Colowick et al., 1951). All measurements were done in triplicates.
APRT Mutagenesis
A human wild-type APRT gene optimized for yeast expression was purchased from DNA2.0 (CA, USA). This gene, flanked by
BglII and NsiI restriction sites, was cloned into a pJ201 vector (DNA2.0) to give the p4489 plasmid. Mutant genes were
obtained by PCR using p4489 as template and oligonucleotides 5’-CTATGGGCATCTTACTCACTTCTATATGGAAAGGCT
GAACTTG-3’ and 5’- CAAGTTCAGCCTTTCCATATAGAAGTGAGTAAGATGCCCATAG-3’ for the E104Lmutant and oligonucleotides
5’-GGGCATCTTACTCACTTGAATTTGGAAAGGCTGAACTTGAAATTC-3’ and 5’-GAATTTCAAGTTCAGCCTTTCCAAATTCAAGTGA
GTAAGATGCCC-3’, for the Y105Fmutant. Wild-type andmutated APRT genes were then cloned into a tetracycline-repressible vec-
tor pCM189 (CEN, URA3) (Gari et al., 1997) by transferring the BglII–NsiI cassette from the pJ201 plasmid into pCM189 opened with
BamHI and PstI, thus giving the p4521, p4911 and p4912 plasmids for wild-type, E104L and Y105F APRT, respectively.
Yeast Medium, Growth Tests and Metabolite Determinations
SD is a synthetic minimal medium which contains 5% ammonium sulfate, 0.17% yeast nitrogen base (BD-Bioscience), 2% glucose.
SDcasaW is SD medium supplemented with 0.2% casamino acids (BD-Bioscience) and tryptophan (0.2 mM). When indicated,
adenine (0.3 mM) or hypoxanthine (0.3 mM) were added in the SDcasaW medium and the resulting media was named SDcasaWA
(+ adenine) or SDcasaWHx (+ hypoxanthine). AMATa ade2 apt1 aah1 ura3 yeast strain (DS1-2B/1, the generous gift of Dr. R.Woods,
University of Winnipeg, Winnipeg, MB, Canada) was transformed with plasmids to allow the expression of wild-type (p4521) and
mutated (p4911 and p4912) versions of human APRT, or the cognate empty vector (pCM189). Transformants were selected on
SDcasaWHx medium and were then used for a drop growth test as described previously (Saint-Marc et al., 2009). For the quantifi-
cation of purines in yeast, transformants were grown exponentially at 30C for 24 h in SDcasaWHx medium. Cells were rapidly har-
vested by filtration (Sartolon polyamid filters 0.45m, Sartorius stedim Biotech, USA) and then incubated for 3 hours at 30C in either
the SDcasaWHx or the SDcasaWA medium. The extraction of the yeast metabolites was done as previously described (Ceschin
et al., 2014) and the metabolite separation was performed on an ICS3000 Chromatography Station (Dionex, Sunnyvale, USA) using
a Carbopac PA1 column (250 x 2 mm; Thermo Electron SAS) with a 50 to 800 mM acetate gradient in 50 mM NaOH as described in
Ceballos-Picot et al. (Ceballos-Picot et al., 2015). Peaks were identified by their retention times and/or their UV spectral signatures as
well as by co-injection with standards. The detection of the human APRT bywestern blotting was done on total yeast protein extracts,
obtained from exponentially grown cells as described in Escusa et al. (Escusa et al., 2006), using anti-human APRT (Abcam,
ab196558) and anti-actin (gracefully given by J.A. Cooper,WashingtonUniversity School ofMedicine, St Louis, MO, USA) antibodies.
QUANTIFICATION AND STATISTICAL ANALYSIS
Cellular adenine, AMP and ATP concentrations were determined from 3 independent metabolite extractions for each condition as
described in the methods. Kinetic data are presented as mean values from three independent experiments and the kinetic param-
eters were determined from the Michaelis-Menten equation. Error bars in all figures show standard deviations.
DATA AND SOFTWARE AVAILABILITY
The atomic coordinates and structure factors for the PRPP-Mg2+-, ADE-PRPP-Mg2+- and AMP-bound hAPRTwt as well as the
hAPRTY105F-14hours, hAPRTY105F-14days and hAPRTY105F-30days complexe structures, reported in this paper, are deposited in the
RCSB Protein Data Bank (www.rcsb.org) under the accession codes 6FCH, 6FCI, 6FCL, 6FD4, 6FD5, 6FD6, respectively.e4 Cell Chemical Biology 25, 666–676.e1–e4, June 21, 2018
